Pulmonx Corporation, a leader in minimally invasive treatments for severe lung diseases, has announced its participation in the upcoming Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, 2026. During this event, the company will engage in a fireside chat, which will be accessible via a live and archived webcast on their website. This is an opportunity for Pulmonx to share insights about their innovative therapies, particularly the Zephyr® Endobronchial Valve, which is designed to improve the quality of life for those suffering from chronic obstructive pulmonary disease (COPD).

For individuals concerned about lung health and aging, this information is particularly relevant. COPD is a progressive disease that can severely impact breathing and overall well-being. The Zephyr Valve has been recognized by the U.S. Food and Drug Administration as a breakthrough device, and it is now a standard treatment option in over 25 countries. This means that people with severe emphysema may find significant relief from symptoms, leading to improved breathing, increased activity levels, and a better quality of life.

While the fireside chat will provide valuable insights into Pulmonx’s ongoing developments, it is important to note that the company is still in the growth phase, and the full impact of their treatments is being evaluated in the medical community. The Zephyr Valve has shown promise, but as with any medical treatment, individuals should consult healthcare professionals to understand the best options for their specific conditions.

For those interested in learning more about Pulmonx and their innovative approaches to lung health, additional information can be found on their website.

Source: GlobeNewswire on Pulmonx’s conference participation